High prevalence of activated protein C resistance due to factor V Leiden mutation in cases of intrauterine fetal death

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 8, Issue 5, 1999, Pages 228-230

  Rothbart, H ^a   Ohel, G ^a,c   Younis, J ^a   Lanir, N ^b   Brenner, B ^b  

^a Poriya Hospital   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

^c BNAI ZION MEDICAL CENTER   (Israel)

Author keywords

Activated protein C resistance; Factor V mutation; Intrauterine fetal death

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5;

ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CONTROLLED STUDY; FETUS; FETUS DEATH; FETUS MORTALITY; GENE MUTATION; HUMAN; PREGNANCY; PRIORITY JOURNAL; THROMBOSIS;

ACTIVATED PROTEIN C RESISTANCE; ADULT; FACTOR V; FEMALE; FETAL DEATH; HETEROZYGOTE; HUMANS; MUTATION;

EID: 0032837985     PISSN: 14767058     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1520-6661(199909/10)8:5<228::aid-mfm6>3.0.co;2-2     Document Type: Article

References (16)

1. Esmon CT. The protein C anticoagulant pathway. Arterioscler Thromb 1992;12:135-145.
2. Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989;264:4743-4746.
3. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993;90:1004.
4. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C. Leiden thrombophilia study. Lancet 1993;342: 1503-1506.
5. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994;330:517.
6. Dahlback B, Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci USA 1994;91:1396-1400.
7. Griffin JH, Evatt B, Widrman C, Fernandez JA. Anticoagulant protein C pathway is defective in majority of thrombophilic patients. Blood 1993;82:1989.
8. Griffin JH, Heeb MJ, Kozima Y, Fernandez JA, Kozima K, Hackeng TM, Greengard JS. Activated protein C resistance: molecular mechanisms. Thromb Haemostas 1995;74:444-448.
9. Brand DW, Scott JR, Kochenour NK, Henshgold E. Obstetric complications associated with the lupus anticoagulant. N Engl J Med 1985;313:1322.
10. Brenner B, Mandel H, Lanir N, Younis J, Rothbart H, Ohel G, Blumenfeld Z. Activated protein C resistance can be associated with recurrent fetal loss. Br J Haematol 1997;97:551-554.
11. Greengard JS, Eichinger S, Griffin JH, Bauer K. Variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg Gln mutation in the gene for factor V. N Engl J Med 1994;331:1559.
12. Seligsohn U, Zivelin A. Thrombophilia as a multigenic disorder. Thromb Haemost 1997;78:297-301.
13. Inante-Rivard C, David M, Gauthier R, Rivard GE. Lupus anticoagulants, anticardiolipin antibodies and fetal loss. N Engl J Med 1991;325: 1063-1066.
14. Dekker GA, de Vries JIP, Doelitzsch PM, Huijgens PC, von Blomberg BME, Jakobs C, van Geijn HP. Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol 1995;173:1042-1048.
15. Mancy A, Pauzner R, Carp H, Langeritz P, Martinowitz U. Treatment of patients with antiphospholipid antibodies during pregnancy. Am J Reprod Immunol 1992;28:216-218.
16. Brenner B, Blumenfeld Z. Thrombophilia and fetal loss. Blood Rev 1997;11:72-79.